Abstract: FR-PO001
Effect of the Seraph® 100 Biomimetic Pathogen Adsorbing Device on Inflammatory Biomarkers in 42 COVID-19 Patients
Session Information
- COVID-19: AKI Outcomes, Biomarkers, Treatments, Case Reports
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Kielstein, Jan T., Academic Teaching Hospital Braunschweig, Braunschweig, Germany
- Dan-Nicolae, Borchina, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
- Schmidt, Julius, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
Background
Lack of pharmacological treatment options in severely ill hospitalized COVID-19 patients prompted explorations of extracorporeal treatments . The Seraph® 100 Microbind® Affinity filter, remove viruses, including SARS-CoV-2 from the blood. Data from an international registry, from a multicenter evaluation in the US, as well as from several case reports suggest that Seraph® 100 can not only be safely used but it may have an impact on patient centered outcome parameters. As it is unknown whether the effect of the Seraph® 100 in COVID-19 patients is solely based on the removal of the virus or, as suggest by a recent observation, by additionally modulating inflammation, we set out to perform a biomarker study.
Methods
We performed this prospective multicenter observational trial at three tertiary care hospitals in patients being treated with Seraph® 100 for severe COVID-19 between June 2020 and April 2021. Biomarkers were obtained before the tretment as well as 2-4 hours after the treatment. as well as 4 days after the Seraph® 100 treatment. Routine clinical chemistry parameters were performed in the respective clinical chemistry labs using certified methods. For the assessment of the inflammatory markers a Bio-Plex Pro Human Cytokine Screening Panel, 48-Plex #12007283 (Bio-Rad) was used.
Results
From June 1st 2020 to April 1st 2021, 42 patients with COVID-19 treated with the Seraph® 100 in our hospitals could be included in the study. Hemoperfusion treatment was initiated in median 3 days after hospital admission. At beginning of the treatment 41/42 (98%) of patients were in the ICU; 8/42 (19%) needed mechanical ventilation, 3/42 (7%) were on additional ECMO support; 27/42 (64%) needed pressors. Seraph® 100 treatment significantly reduced d-dimer comparing pre-treatment data with data obtained 2-4 hours after treatment
Four days after treatment hemoglobin, LDH, D-dimer, troponin and ferritin were significant reduced. From the interleukin assay IL-1b, IL8, IL-10, IL-13, IL-15, Eotaxin, G-CSF and IP-10 were significantly reduced 2-4 hours after treatment, but not 4 days later. The median hospital stay was 20 days. After 3 months 20/42 (48%) of patients had died.
Conclusion
In conclusion, our data show that Seraph® 100 leads to a significant reduction of biomarkers that are either predictive of adverse outcome or the severity COVID-19.